Verona Pharma (VRNA) Stock Forecast & Price Target

Q: What is VRNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Verona Pharma Plc’s 12-month average price target is 112.22.

Q: What is VRNA’s upside potential, based on the analysts’ average price target?

Verona Pharma Plc has 17.99% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is VRNA a Buy, Sell or Hold?

Verona Pharma Plc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

Q: What is Verona Pharma Plc’s price target?

The average price target for Verona Pharma Plc is 112.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $160.00 ,the lowest forecast is $90.00. The average price target represents 17.99% Increase from the current price of $95.11.

Q: What do analysts say about Verona Pharma Plc?

Verona Pharma Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

Q: How can I buy shares of VRNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

812 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRNA Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Verona

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRNA Stock 12 Month Forecast

Average Price Target

$112.22

▲(17.99%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Verona Pharma in the last 3 months. The average price target is $112.22 with a high forecast of $160.00 and a low forecast of $90.00. The average price target represents a 17.99% change from the last price of $95.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","86":"$86","161":"$161","48.5":"$48.5","123.5":"$123.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$160.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$112.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,48.5,86,123.5,161],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.1,89.93846153846154,95.77692307692307,101.61538461538461,107.45384615384614,113.29230769230769,119.13076923076923,124.96923076923076,130.80769230769232,136.64615384615385,142.48461538461538,148.32307692307694,154.16153846153847,{"y":160,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.1,86.26307692307692,88.42615384615384,90.58923076923077,92.75230769230768,94.91538461538461,97.07846153846154,99.24153846153845,101.40461538461538,103.56769230769231,105.73076923076923,107.89384615384616,110.05692307692308,{"y":112.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.1,84.55384615384615,85.00769230769231,85.46153846153845,85.91538461538461,86.36923076923077,86.82307692307693,87.27692307692307,87.73076923076923,88.18461538461538,88.63846153846154,89.09230769230768,89.54615384615384,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.07,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.11,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$160.00

Average Price Target$112.22

Lowest Price Target$90.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yasmeen RahimiPiper Sandler

Piper Sandler

$76→$160

Buy

68.23%

Upside

Reiterated

06/23/25

Verona Pharma price target raised to $160 from $76 at Piper SandlerVerona Pharma price target raised to $160 from $76 at Piper Sandler

Tiago FauthWells Fargo

Wells Fargo

$107→$138

Buy

45.10%

Upside

Reiterated

06/20/25

Strong Buy Rating for Verona Pharma's Ohtuvayre Amidst Undervalued Peak Sales Potential and Growing Market Demand

Boobalan PachaiyappanRoth MKM

Roth MKM

$92→$116

Buy

21.96%

Upside

Reiterated

06/18/25

Verona Pharma price target raised to $116 from $92 at Roth CapitalVerona Pharma price target raised to $116 from $92 at Roth Capital

Andrew TsaiJefferies

Jefferies

$95→$110

Buy

15.66%

Upside

Reiterated

06/11/25

Verona Pharma price target raised to $110 from $95 at JefferiesVerona Pharma price target raised to $110 from $95 at Jefferies

Olivia BrayerCantor Fitzgerald

Cantor Fitzgerald

$90→$100

Buy

5.14%

Upside

Reiterated

06/11/25

Verona Pharma (VRNA) Receives a Buy from Cantor Fitzgerald

Tara BancroftTD Cowen

TD Cowen

$100

Buy

5.14%

Upside

Reiterated

06/11/25

Verona Pharma (VRNA) Receives a Buy from TD Cowen

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$85→$90

Buy

-5.37%

Downside

Reiterated

06/02/25

Verona Pharma's Ohtuvayre Positioned for Market Dominance Amid Reduced Competition

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/21/25

Verona Pharma (VRNA) Receives a Buy from Truist Financial

Edward NashCanaccord Genuity

Canaccord Genuity

$72→$106

Buy

11.45%

Upside

Reiterated

04/30/25

Verona Pharma price target raised to $106 from $72 at CanaccordVerona Pharma price target raised to $106 from $72 at Canaccord

Thomas ShraderBTIG

BTIG

$83→$90

Buy

-5.37%

Downside

Reiterated

04/30/25

Verona Pharma price target raised to $90 from $83 at BTIGVerona Pharma price target raised to $90 from $83 at BTIG

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yasmeen RahimiPiper Sandler

Piper Sandler

$76→$160

Buy

68.23%

Upside

Reiterated

06/23/25

Verona Pharma price target raised to $160 from $76 at Piper SandlerVerona Pharma price target raised to $160 from $76 at Piper Sandler

Tiago FauthWells Fargo

Wells Fargo

$107→$138

Buy

45.10%

Upside

Reiterated

06/20/25

Strong Buy Rating for Verona Pharma's Ohtuvayre Amidst Undervalued Peak Sales Potential and Growing Market Demand

Boobalan PachaiyappanRoth MKM

Roth MKM

$92→$116

Buy

21.96%

Upside

Reiterated

06/18/25

Verona Pharma price target raised to $116 from $92 at Roth CapitalVerona Pharma price target raised to $116 from $92 at Roth Capital

Andrew TsaiJefferies

Jefferies

$95→$110

Buy

15.66%

Upside

Reiterated

06/11/25

Verona Pharma price target raised to $110 from $95 at JefferiesVerona Pharma price target raised to $110 from $95 at Jefferies

Olivia BrayerCantor Fitzgerald

Cantor Fitzgerald

$90→$100

Buy

5.14%

Upside

Reiterated

06/11/25

Verona Pharma (VRNA) Receives a Buy from Cantor Fitzgerald

Tara BancroftTD Cowen

TD Cowen

$100

Buy

5.14%

Upside

Reiterated

06/11/25

Verona Pharma (VRNA) Receives a Buy from TD Cowen

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$85→$90

Buy

-5.37%

Downside

Reiterated

06/02/25

Verona Pharma's Ohtuvayre Positioned for Market Dominance Amid Reduced Competition

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/21/25

Verona Pharma (VRNA) Receives a Buy from Truist Financial

Edward NashCanaccord Genuity

Canaccord Genuity

$72→$106

Buy

11.45%

Upside

Reiterated

04/30/25

Verona Pharma price target raised to $106 from $72 at CanaccordVerona Pharma price target raised to $106 from $72 at Canaccord

Thomas ShraderBTIG

BTIG

$83→$90

Buy

-5.37%

Downside

Reiterated

04/30/25

Verona Pharma price target raised to $90 from $83 at BTIGVerona Pharma price target raised to $90 from $83 at BTIG

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Verona Pharma

1 Month

xxx

Success Rate

12/16 ratings generated profit

Average Return

+13.46%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +13.46% per trade.

3 Months

xxx

Success Rate

13/16 ratings generated profit

Average Return

+35.13%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 81.25% of your transactions generating a profit, with an average return of +35.13% per trade.

1 Year

Ram SelvarajuH.C. Wainwright

Success Rate

16/16 ratings generated profit

Average Return

+221.83%

reiterated a buy rating 25 days ago

Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +221.83% per trade.

2 Years

xxx

Success Rate

16/16 ratings generated profit

Average Return

+335.04%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +335.04% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRNA Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRNA has received 19 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VRNA average Analyst price target in the past 3 months is 112.22.

Each month's total comprises the sum of three months' worth of ratings.

VRNA Financial Forecast

VRNA Earnings Forecast

Next quarter’s earnings estimate for VRNA is <$0.01 with a range of -$0.17 to $0.39. The previous quarter’s EPS was -$0.02. VRNA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.15% of the time in the same period. In the last calendar year VRNA has Outperformed its overall industry.

VRNA Sales Forecast

Next quarter’s sales forecast for VRNA is $92.85M with a range of $83.00M to $105.97M. The previous quarter’s sales results were $76.55M. VRNA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year VRNA has Outperformed its overall industry.

VRNA Stock Forecast FAQ

What is VRNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Verona Pharma Plc’s 12-month average price target is 112.22.

What is VRNA’s upside potential, based on the analysts’ average price target?

Verona Pharma Plc has 17.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRNA a Buy, Sell or Hold?

Verona Pharma Plc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Verona Pharma Plc’s price target?

The average price target for Verona Pharma Plc is 112.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $160.00 ,the lowest forecast is $90.00. The average price target represents 17.99% Increase from the current price of $95.11.

What do analysts say about Verona Pharma Plc?

Verona Pharma Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of VRNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Verona Pharma (VRNA) Stock Forecast & Price Target

VRNA Analyst Ratings

VRNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Verona Pharma

VRNA Analyst Recommendation Trends

VRNA Financial Forecast

VRNA Earnings Forecast

VRNA Sales Forecast

VRNA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts